Damora Therapeutics, Inc. (DMRA) - Total Assets
Based on the latest financial reports, Damora Therapeutics, Inc. (DMRA) holds total assets worth $260.53 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Damora Therapeutics, Inc. stock price for real-time trading data and today's change.
Damora Therapeutics, Inc. - Total Assets Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see DMRA operating cash flow for how efficiently the company converts equity into cash flow.
Damora Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Damora Therapeutics, Inc.'s total assets of $260.53 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.9% |
| Accounts Receivable | $899.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore DMRA current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Damora Therapeutics, Inc.'s current assets represent 100.0% of total assets in 2025, an increase from 99.6% in 2018.
- Cash Position: Cash and equivalents constituted 98.9% of total assets in 2025, up from 88.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Damora Therapeutics, Inc. Competitors by Total Assets
Key competitors of Damora Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
Damora Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.98 | 14.07 | 21.10 |
| Quick Ratio | 12.98 | 14.07 | 21.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $240.36 Million | $15.64 Million | $111.36 Million |
Damora Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Damora Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 163.79 |
| Latest Market Cap to Assets Ratio | 5.59 |
| Asset Growth Rate (YoY) | 1420.7% |
| Total Assets | $260.53 Million |
| Market Capitalization | $1.46 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Damora Therapeutics, Inc.'s assets at a significant premium (5.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Damora Therapeutics, Inc.'s assets grew by 1420.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Damora Therapeutics, Inc. (2018–2025)
The table below shows the annual total assets of Damora Therapeutics, Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $260.53 Million | +1420.70% |
| 2024-12-31 | $17.13 Million | -55.18% |
| 2023-12-31 | $38.23 Million | -47.77% |
| 2022-12-31 | $73.19 Million | -40.12% |
| 2021-12-31 | $122.22 Million | -28.78% |
| 2020-12-31 | $171.60 Million | +203.12% |
| 2019-12-31 | $56.61 Million | +61.26% |
| 2018-12-31 | $35.10 Million | -- |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more